Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SYGNIS Granted US Patent for QUALIPHI®

Published: Monday, June 03, 2013
Last Updated: Monday, June 03, 2013
Bookmark and Share
New patent opens SYGNIS and QUALIPHI® in a leading position in a €70 million global market.

SYGNIS Pharma AG has been granted a patent by the USPTO (US patent and Trademark office) for its flagship product, QUALIPHI® the polymerase for complete DNA amplification.

Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are a basic need for research involving the analysis and modification of DNA.

QUALIPHI® is an upgraded version of the Phi 29 DNA polymerase used in isothermal amplification which provides enhanced properties compared to similar polymerase proteins on the market.

Being less time-consuming and having highly superior performance characteristics, the method developed by SYGNIS enables DNA amplification from concentrations as low as those found in a single cell. This is extremely useful in cancer research, and many other applications.

“Certainly, the need for amplification of nucleic acids from minimal concentrations as present in single cell applications will be a critical issue in the coming era of personalized medicine and NGS. We expect QUALIPHI® to become an essential tool for the DNA amplification needed in these markets”, said SYGNIS’ CEO, Pilar de la Huerta.

With the significant growth in the field of DNA amplifications used in sequencing and personalized medicine, the market of whole genome amplification with polymerase proteins is expected to grow at over 20% per annum over the next few years.

Current estimates indicate that the size of the global isothermal DNA market alone is approximately €70 million, with the US as the leading market for QUALIPHI®.

In 2012,SYGNIS granted an exclusive global licence to QIAGEN, including sublicensing rights, for the commercialization of QUALIPHI® in the DNA amplification market. QIAGEN is a global leader in sample and assay technologies in research and molecular diagnostics.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!